Full Breakdown
Poll Shows Majority Prioritize Safety Over Access to Mifepristone
6/25/2026, 1:31:20 AM
Key Findings of the YouGov Poll
The YouGov poll commissioned by Americans United for Life surveyed 1,000 U.S. adults. Sixty-eight percent said patient safety should outweigh ease of access to mifepristone, while 67 % favored stronger safeguards. Eighty-six percent supported mandatory informed-consent counseling. Forty-one percent answered “don’t know,” and a plurality still wanted the medication available. Only four in ten approved shipping the pill across state lines.
Regulatory Background
Mifepristone received FDA approval in 2000 with a seven-week limit, required an in-person doctor visit, and mandated adverse-event reporting. In 2021 the FDA allowed mail-order under a REMS, then removed the in-person dispensing rule, permitting mail shipment. These changes followed the 2022 Dobbs decision returning abortion regulation to the states.
Key Statistics
About 63-65 % of U.S. abortions now involve mifepristone and misoprostol, and total abortions have risen to roughly 1.13-1.14 million annually. A Charlotte Lozier Institute survey of medication-abortion patients reported that roughly half wanted more information on bleeding, pain, and mental-health effects. In Louisiana, a father allegedly poisoned his pregnant daughter with abortion pills, leading to an emergency C-section.
Official Statements & Responses
AUL officials said the poll shows demand for stronger safety protocols and that the Biden administration’s removal of in-person dispensing eliminated a key guarantee of informed consent. They also call for mandatory ultrasound confirmation, ectopic-pregnancy screening, and post-procedure follow-up, arguing remote prescribing compromises these safeguards.
Criticism & Opposition
Critics note the poll’s AUL funding may shape question wording and that it omitted safety assessment for the drug’s intended victims. The 41 % “don’t know” response signals notable public uncertainty about the medication’s risk profile.
Conflicting Reports & Data Gaps
The FDA no longer requires reporting of non-fatal adverse events for mifepristone, limiting safety data. Industry ads claim the drug is “safer than Tylenol or Viagra,” yet independent studies on adverse-event rates remain limited. Consequently, the poll’s safety emphasis reflects perception rather than comprehensive clinical evidence.
Verbatim Quotes
- “Since the Dobbs decision, abortion advocates have tried to convince women that access matters more than our own safety,” — Sarah Zagorski, AUL senior director of PR and communications
- “More than two-thirds of Americans have rejected that deception.” — Sarah Zagorski, AUL senior director of PR and communications
- “When the Biden administration removed in-person dispensing requirements for mifepristone, they removed any guarantee that women receive informed consent,” — John Mize, CEO of Americans United for Life
- “ 86% of respondents said health care providers should properly educate patients and obtain informed consent before prescribing the abortion pill.” — YouGov poll commissioned by Americans United for Life
Future Outlook
Pro-life states are drafting bills to restrict mail-order distribution and require in-person evaluation, while other states have passed shield laws protecting providers who ship pills across state lines. FDA rulemaking and federal court challenges will shape mifepristone’s regulatory future in coming months.
